Apply to trial NCT06684522

A few quick questions so the study team can decide if you might be a fit.

RecruitingEarly Phase 1Drug trial

Upadacitinib as a Novel Treatment for Refractory Eyelid Dermatitis

This study aims to assess the efficacy of upadacitinib in eyelid dermatitis that has not resolved with topical therapies and patch testing.

How this works

  1. Answer a few questions

    About 5 to 10 minutes. Skip-friendly where possible.

  2. We forward your profile to the study team

    They see only the answers needed to decide if you can be screened.

  3. The team reaches out to schedule screening

    Usually within a few business days, via the contact you give.

We save your progress under this email so you can come back later, and the study team uses it to reach you.

By clicking Start, you agree to our terms of service.